title: What are the Considerations in Balancing Benefits and Risks in Iron Treatment?: How Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitors May Change Iron Management in End-Stage Renal Disease.
authors.affiliation: FibroGen, Inc., San Francisco, California.
authors.forename: Anatole
authors.initials: A
authors.lastname: Besarab
authors.affiliation: FibroGen, Inc., San Francisco, California.
authors.forename: Lynda
authors.initials: L
authors.lastname: Szczech
mesh_terms: D061605:Administration, Intravenous; D000284:Administration, Oral; D018798:Anemia, Iron-Deficiency / Q000209:etiology* / Q000628:therapy*; D006801:Humans; D058085:Iron Compounds / Q000008:administration & dosage*; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000628:therapy; D064800:Prolyl-Hydroxylase Inhibitors / Q000627:therapeutic use*; D018570:Risk Assessment
chemical_list: D058085:Iron Compounds; D064800:Prolyl-Hydroxylase Inhibitors